Bookbuilding IPO | ₹700 Cr | Listed at BSE, NSE | Thu, Dec 16, 2021 - Mon, Dec 20, 2021
Supriya Lifescience IPO is a book build issue of ₹700.00 crores. The issue is a combination of fresh issue of 0.73 crore shares aggregating to ₹200.00 crores and offer for sale of 1.82 crore shares aggregating to ₹500.00 crores.
Supriya Lifescience IPO bidding started from Dec 16, 2021 and ended on Dec 20, 2021. The allotment for Supriya Lifescience IPO was finalized on Dec 23, 2021. The shares got listed on BSE, NSE on Dec 28, 2021.
Supriya Lifescience IPO price band is set at ₹274 per share. The lot size for an application is 54. The minimum amount of investment required by an retail is ₹14,796 (54 shares) (based on upper price). The lot size investment for sNII is 14 lots (756 shares), amounting to ₹2,07,144, and for bNII, it is 68 lots (3,672 shares), amounting to ₹10,06,128.
Axis Capital Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue.
Refer to Supriya Lifescience IPO RHP for detailed Information.
IPO Open
Thu, Dec 16, 2021
IPO Close
Mon, Dec 20, 2021
Issue Price
₹274 per share
Market Cap (Pre-IPO)
₹700.00 Cr
| IPO Date | 16 to 20 Dec, 2021 |
| Listed on | Tue, Dec 28, 2021 |
| Face Value | ₹2 per share |
| Price Band | ₹265 to ₹274 |
| Issue Price | ₹274 per share |
| Lot Size | 54 Shares |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | 2,55,47,445 shares (agg. up to ₹700 Cr) |
| Fresh Issue | 72,99,270 shares (agg. up to ₹200 Cr) |
| Offer for Sale | 1,82,48,175 shares of ₹2 (agg. up to ₹500 Cr) |
| Share Holding Pre Issue | 7,31,83,530 shares |
| Share Holding Post Issue | 2,55,47,445 shares |
| BSE Script Code / NSE Symbol | 543434 / SUPRIYA |
| ISIN | INE07RO01027 |
Supriya Lifescience IPO comprises a total issue size of 2,55,47,445 shares. Out of which, 1,91,60,585 (75.00%) are allocated to QIB, 38,32,116 (15.00%) allocated to NII 25,54,744 (10.00%) allocated to RII.
| Investor Category | Shares Offered | % of Total Issue | Max Allottees |
|---|---|---|---|
| QIB Shares Offered | 1,91,60,585 | 75.00% | NA |
| − Anchor Investor Shares Offered | 1,14,96,351 | 45.00% | NA |
| − QIB (Ex. Anchor) Shares Offered | 76,64,234 | 30.00% | NA |
| NII (HNI) Shares Offered | 38,32,116 | 15.00% | NA |
| Retail Shares Offered | 25,54,744 | 10.00% | 47,310 |
| Total Shares Offered | 2,55,47,445 | 100.00% |
Investors can bid for a minimum of 54 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 54 | ₹14,796 |
| Retail (Max) | 13 | 702 | ₹1,92,348 |
| S-HNI (Min) | 14 | 756 | ₹2,07,144 |
| S-HNI (Max) | 67 | 3,618 | ₹9,91,332 |
| B-HNI (Min) | 68 | 3,672 | ₹10,06,128 |
Supriya Lifescience IPO raises ₹315.00 crore from anchor investors. Supriya Lifescience IPO Anchor bid date is December 15, 2021.
📝 Anchor Investors Letter (PDF)
| Bid Date | Wed, Dec 15, 2021 |
| Shares Offered | 1,14,96,351 |
| Anchor Portion (₹ Cr.) | 315.00 |
| Anchor lock-in period end date for 50% shares (30 Days) | Sat, Jan 22, 2022 |
| Anchor lock-in period end date for remaining shares (90 Days) | Wed, Mar 23, 2022 |
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. The company has been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India between Fiscal 2017 and 2021. The company is also one of the largest exporters of Salbutamol Sulphate from India in FY 2021 in terms of volume.
In Fiscal 2021, the company's products were exported to 86 countries to 1,296 customers including 346 distributors. The company has API business in Europe, Latin America, Asia, and North America.
Supriya Lifescience has a modern manufacturing facility in Maharashtra spread across 23,806 sq. mts, having a reactor capacity of 547 KL/ day including 7 clean rooms. The company has also acquired a plot of land, admeasuring 12,551 sq. mt, near the present manufacturing facility, to expand its manufacturing infrastructure. The company's manufacturing facility has received approvals from USFDA, EDQM TGA-Australia, KFDA-Korea, PMDA Japan, NMPA (previously known as SFDA)- China, Health Canada, in relation to API products being exported to the relevant jurisdictions by the company.
| Period Ended |
|---|
| Amount in ₹ Crore |
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure requirements of the Company; | 92.30 |
| 2 | Repayment and/ or pre-payment, in full or part, of certain borrowings availed by the Company | 60.00 |
| 3 | General corporate purposes. | 35.95 |
The Supriya Lifescience IPO is subscribed 71.51 times on December 20, 2021 7:52:00 PM (Day 4). The public issue subscribed 56.01 times in the retail category, 31.83 times in the QIB category, and 161.22 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (x) | Shares Offered | Shares bid for |
|---|---|---|---|
| QIB (Ex Anchor) | 31.83 | 79,24,527 | 25,22,34,270 |
| NII | 161.22 | 39,62,263 | 63,87,80,418 |
| Retail | 56.01 | 26,41,509 | 14,79,42,450 |
| Total | 71.51 | 1,45,28,299 | 1,03,89,57,138 |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | BRLMs fees and commissions (including underwriting commission) | 16.52 |
| 2 | Commission/processing fee for SCSBs, Sponsor Bank and Bankers to the Offer. Brokerage and selling commission and bidding charges for Members of the Syndicate, Registered Brokers, RTAs and CDPs | 5.86 |
| 3 | Fees payable to the Registrar to the Offer | 1.21 |
| 4 | Fees payable to the other advisors to the Offer | 0.53 |
| 5 | Others | |
| 6 | - Listing fees, SEBI filing fees, upload fees, BSE & NSE processing fees, book building software fees and other regulatory expenses | 3.37 |
| 7 | - Printing and stationery | 2.53 |
| 8 | - Advertising and marketing expenses | 5.59 |
| 9 | - Fee payable to legal counsels | 2.95 |
| 10 | - Miscellaneous | 2.56 |
| Price Details | BSE | NSE |
|---|---|---|
| Final Issue Price | ₹274.00 | ₹274.00 |
| Open | ₹425.00 | ₹421.00 |
| Low | ₹383.15 | ₹383.20 |
| High | ₹425.00 | ₹421.00 |
| Last Trade | ₹390.35 | ₹390.85 |
Lead Manager Reports
Supriya Lifescience IPO is a main-board IPO of 2,55,47,445 equity shares of the face value of ₹2 aggregating up to ₹700 Crores. The issue is priced at ₹274 per share. The minimum order quantity is 54.
The IPO opens on Thu, Dec 16, 2021, and closes on Mon, Dec 20, 2021.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Supriya Lifescience IPO using UPI as a payment gateway. Zerodha customers can apply in Supriya Lifescience IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Supriya Lifescience IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Supriya Lifescience IPO opens on Thu, Dec 16, 2021 and closes on Mon, Dec 20, 2021.
Supriya Lifescience IPO lot size is 54, and the minimum amount required for application is ₹14,796.
You can apply in Supriya Lifescience IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Supriya Lifescience IPO will be done on Thursday, December 23, 2021, and the allotted shares will be credited to your demat account by Mon, Dec 27, 2021. Check the Supriya Lifescience IPO allotment status.
The Supriya Lifescience IPO listing date is on Tue, Dec 28, 2021.
